Combination of Targeted Radionuclide Therapy and Checkpoint Blockade Augments Therapeutic Response in a Syngeneic Murine Model of Melanoma

Conclusions:In a preclinical syngeneic murine melanoma model, we demonstrate a cooperative therapeutic effect with combined TRT and CB. This confirms that systemic administration of 90Y-NM600 can deliver an immunomodulatory radiation dose to the tumor microenvironment without inducing systemic immunosuppression. We are now testing this approach in similar preclinical studies in combination with other immunotherapies and in the setting of disseminated metastatic disease.

Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Hernandez, R., Patel, R., Grudzinski, J., Carlson, P., Sriramaneni, R., Brown, R., Bednarz, B., Sondel, P., Morris, Z., Weichert, J. Tags: Center for Therapy Excellence YIA Symposium Source Type: research